Author:
Chaaban Sarah,Istvan Marion,Schreck Benoit,Laigo Pauline,Rousselet Morgane,Grall-Bronnec Marie,Pain Stéphanie,Victorri-Vigneau Caroline
Abstract
Abstract
Background
Chronic use of cannabis is associated with an increased risk of psychosocial, mental and physical health impairments. Sociohealth institutions reach a very limited proportion of cannabis users in need of treatment. Using data collected from festival attendees, this study aimed to estimate the prevalence of dependent cannabis users and to characterize cannabis dependence.
Methods
We used data from the cross-sectional OCTOPUS survey carried out at 13 music events in the French department of Loire-Atlantique between July 2017 and July 2018. 383 participants aged 18 or older underwent a face-to-face interview about their basic sociodemographics, tobacco use, alcohol use and past-year substance use. Using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, we estimated the prevalence of dependent cannabis users and characterized their dependence.
Results
More than two-thirds of participants reported that they had used cannabis in the past 12 months. Among 194 regular cannabis users (at least monthly), 63.4% were dependent. At least 40% of regular users reported health and/or social consequences of cannabis use. Compared to nondependent cannabis users, dependent cannabis users were more likely to be stimulant users and hallucinogen users.
Conclusions
Dependent cannabis use is common among festival attendees, especially among stimulant or hallucinogen users. Festival settings may be important arenas for i) implementing efficient harm reduction measures to prevent dependence and ii) providing information on care structures and promoting the use of care to dependent users. In addition, healthcare professionals should be aware of trends in polysubstance use among dependent cannabis users.
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.
2. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021 : Trends and Development [Internet]. 2021. Available from: https://www.emcdda.europa.eu/system/files/media/publications/documents/13838/2021.2256_FR_02_.pdf. Accessed 12 Mar 2024.
3. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2023 [Internet]. LU: Publications Office; 2023 [cited 2024 Mar 12]. (European drug report ... (Online)). (Online)). Available from: https://data.europa.eu/doi/10.2810/161905.
4. Le Nézet O, Spilka S, Lahaie E, Andler R. Les usages de cannabis en population adulte en 2021 [Internet]. 2022. Available from: https://www.ofdt.fr/BDD/publications/docs/eftxol2cc.pdf .
5. Galván G, Guerrero-Martelo M, Vásquez De la Hoz F. Cannabis: A Cognitive Illusion. Rev Colomb Psiquiatr. 2017;46(2):95–102.